Aromatase inhibitors are associated with a higher fracture risk than tamoxifen: a systematic review and meta-analysis

Olivia L. Tseng, John J. Spinelli, Carolyn C. Gotay, Wan Y. Ho, Mary L. McBride, Martin G. Dawes
  • Therapeutic Advances in Musculoskeletal Disease, March 2018, SAGE Publications
  • DOI: 10.1177/1759720x18759291

Aromatase inhibitors are associated with a higher risk of broken bones than tamoxifen

What is it about?

Hormonal treatments such as tamoxifen and aromatase inhibitors (Anastrozole, Letrozole and Exemestane) are commonly provided to women diagnosed with breast cancer. This paper summarized information from 21 studies to evaluate the effects of hormonal treatments on the women’s bones.

Why is it important?

An additional 35 in every 100 women taking aromatase inhibitor treatment will exhibit broken bones compared with women taking tamoxifen treatment. Broken bones are more likely to happened during the treatment period.

Read Publication

The following have contributed to this page: Olivia Tseng